Latest news
The BioPharm Brief: Fast Tracks, Triple Targets, and Second Chances - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 23:29:20 GMTFAQ: What mFLUSIVA's Approval May Signal for the Future of mRNA Vaccine Development - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 21:11:05 GMTWhy Talent and Market Access Should Drive Biotech Location Decisions - BioPharm InternationalBioPharm International · Thu, 06 Aug 2026 23:57:23 GMTModerna's mFLUSIVA Approval Validates mRNA Platform Beyond COVID-19: What It Means for Biopharmaceutical Manufacturing - BioPharm InternationalBioPharm International · Thu, 06 Aug 2026 16:59:36 GMTApplied Biologics Gains IRB Approval for Phase 3 BIOxHEAL Trial in Diabetic Foot Ulcers - BioPharm InternationalBioPharm International · Wed, 05 Aug 2026 21:15:33 GMTNavigating Biopharma Complexity: Why Long-Term Partnerships Matter - BioPharm InternationalBioPharm International · Tue, 04 Aug 2026 10:28:23 GMT